White Paper
26.07.2026
Conflict-of-interest management rules and implicat...

Executive Summary Rare disease assessments rely on specialist clinical and patient expertise to inte...

Read more
Webinar
22.07.2026
Design Once, Adapt Smartly Aligning NICE and JCA e...

As NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...

Read more
Webinar
01.07.2026
Dissecting the First EU Joint Clinical Assessment ...

The first EU Joint Clinical Assessment (JCA) has now been published, providing the first practical i...

Read more
Poster
10.06.2026
A comparison of conflict-of-interest (CoI) managem...

Expert contributions are critical to health technology assessment (HTA), particularly in rare diseas...

Read more
News
03.12.2025
Joint Scientific Consultations 2026 – key dates ...

The HTA Coordination Group (HTACG) has now confirmed the 2026 request periods for joint scientific c...

Read more
Poster
15.10.2025
What Are the Likely PICOs for Tovorafenib and Lifi...

Objectives:  ​​EUHTA regulation has applied from the 1st January 2025 for oncology pr...

Read more
Poster
15.10.2025
How the EU JCA could interface with Regional Prici...

Objectives: ​​To analyse how the mandatory EU Joint Clinical Assessment (JCA) could in...

Read more
Articles
08.09.2025
The JCA is here – are you generating the right e...

Five success pillars — your JCA evidence-generation checklist  From 12th January 2025, the Eu...

Read more
Articles
11.08.2025
Why your PICO strategy matters to successful JCA 

The Joint Clinical Assessment (JCA), a core feature of the Regulation (EU) 2021/2282, aims to stream...

Read more
Webinar
07.11.2024
Breaking new ground: key learnings from one of the...

Remap Consulting presents ground-breaking insights and practical learnings from one of the pioneerin...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.